|Articles|October 17, 2005

To make the Biggest difference Table 2 Cont.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Subscribe Now!

Related Content

FDA approves gepotidacin as oral treatment for urogenital gonorrhea

ByMorgan Ebert, Managing Editor

December 11th 2025

Reports: FDA launching safety review of nirsevimab and clesrovimab for RSV

ByJoshua Fitch, Senior Editor

December 11th 2025

Full case: A slender teen with a growing abdomen and shrinking height velocity

ByVanessa Victor-Linkenhoker, MD,Jessica Lamie, OMS-IV,Marie Nicole Antonios, OMS-IV

December 10th 2025

Joshua Feder, MD, on presenting DRBIs, NDBIs, as options in addition to applied behavioral analysis

ByJoshua Feder, MD

December 10th 2025

FDA approves Waskyra as first gene therapy for Wiskott-Aldrich syndrome

ByJoshua Fitch, Senior Editor

December 10th 2025

Latest CME

Multimedia

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

Frank B. Cortazar, MD; Lindsay S. Lally, MD

In-Person + Virtual Event

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

January 23, 2026

Video

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Video

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP; Anders Carlson, MD; Jennifer B. Green, MD

Video

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

To make the Biggest difference Table 2 Cont.

Newsletter

Related Content

FDA approves gepotidacin as oral treatment for urogenital gonorrhea

Reports: FDA launching safety review of nirsevimab and clesrovimab for RSV

Full case: A slender teen with a growing abdomen and shrinking height velocity

Joshua Feder, MD, on presenting DRBIs, NDBIs, as options in addition to applied behavioral analysis

FDA approves Waskyra as first gene therapy for Wiskott-Aldrich syndrome

Latest CME

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Trending on Contemporary Pediatrics

FDA approves Waskyra as first gene therapy for Wiskott-Aldrich syndrome

FDA approves gepotidacin as oral treatment for urogenital gonorrhea

Vaccines in childhood linked to lower drug-resistant bacteria risk

Can you diagnose this slender teen with a growing abdomen and shrinking height velocity?

Reports: FDA launching safety review of nirsevimab and clesrovimab for RSV